<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114338">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920867</url>
  </required_header>
  <id_info>
    <org_study_id>ICMS-2013-0019.</org_study_id>
    <nct_id>NCT01920867</nct_id>
  </id_info>
  <brief_title>Stem Cell Ophthalmology Treatment Study</brief_title>
  <acronym>SCOTS</acronym>
  <official_title>Bone Marrow Derived Stem Cell Ophthalmology Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Associates of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MD Stem Cells</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Associates of South Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the
      treatment of retinal and optic nerve damage or disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eyes with loss of vision from retinal or optic nerve conditions generally considered
      irreversible will be treated with a combination of injections of autologous bone marrow
      derived stem cells isolated from the bone marrow using standard medical and surgical
      practices. Retinal conditions may include degenerative, ischemic or physical damage (
      examples may include macular degeneration, hereditary retinal dystrophies such as retinitis
      pigmentosa, stargardt, non-perfusion retinopathies, post retinal detachment. Optic Nerve
      conditions may include degenerative, ischemic or physical damage ( examples may include
      optic nerve damage from glaucoma, compression, ischemic optic neuropathy, optic atrophy ).
      Injections may include retrobulbar, subtenon, intravitreal, intraocular, subretinal and
      intravenous. Patients will be followed for 12 months with serial comprehensive eye
      examinations including relevant imaging and diagnostic ophthalmic testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 day to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best corrected visual acuity will be measured with Snellen Eye Chart and the ETDRS (Early Treatment Diabetic Retinopathy Study)Eye Chart when available at each post- procedure visit. Intervals at minimum will be first post- procedure day,then 3 months, 6 months and 12 months  post-procedure day.  Recommended visit 1 month post -procedure day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual fields</measure>
    <time_frame>1 day to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual fields will be evaluated with automated perimetry during post- procedure visits as needed and specifically at 6 months and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Macular Degeneration</condition>
  <condition>Hereditary Retinal Dystrophy</condition>
  <condition>Optic Nerve Disease</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>RB, ST, IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RB, ST, IV, IVIT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal (IVIT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RB, ST, IV, IO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RB (Retrobulbar)</intervention_name>
    <description>Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)</description>
    <arm_group_label>RB, ST, IV</arm_group_label>
    <arm_group_label>RB, ST, IV, IVIT</arm_group_label>
    <arm_group_label>RB, ST, IV, IO</arm_group_label>
    <other_name>Retrobulbar injection of stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ST (Subtenon)</intervention_name>
    <description>Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)</description>
    <arm_group_label>RB, ST, IV</arm_group_label>
    <arm_group_label>RB, ST, IV, IVIT</arm_group_label>
    <arm_group_label>RB, ST, IV, IO</arm_group_label>
    <other_name>Subtenon injection of stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IV (Intravenous)</intervention_name>
    <description>Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)</description>
    <arm_group_label>RB, ST, IV</arm_group_label>
    <arm_group_label>RB, ST, IV, IVIT</arm_group_label>
    <arm_group_label>RB, ST, IV, IO</arm_group_label>
    <other_name>Intravenous injection of stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVIT (Intravitreal)</intervention_name>
    <description>Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)</description>
    <arm_group_label>RB, ST, IV, IVIT</arm_group_label>
    <other_name>Intravitreal injection of stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IO (Intraocular)</intervention_name>
    <description>Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity or subretinal injections of stem cells.</description>
    <arm_group_label>RB, ST, IV, IO</arm_group_label>
    <other_name>Intraocular injection of stem cells with vitrectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have objective, documented damage to the retina or optic nerve unlikely to improve OR

          -  Have objective, documented damage to the retina or optic nerve that is progressive

          -  AND have less than or equal to 20/40 best corrected central visual acuity in one or
             both eyes AND/OR an abnormal visual field in one or both eyes.

          -  Be at least 3 months post-surgical treatment intended to treat any ophthalmologic
             disease and stable.

          -  If under current medical therapy ( pharmacologic treatment)  for a retinal or optic
             nerve disease be considered stable on that treatment and unlikely to have visual
             function improvement ( for example, glaucoma with intraocular pressure stable on
             topical medications but visual field damage ).

          -  Have the potential for improvement with BMSC treatment and be at minimal risk of any
             potential harm from the procedure.

          -  Be over the age of 18

          -  Be medically stable and able to be medically cleared by their primary care physician
             or a licensed primary care practitioner for the procedure.  Medical clearance means
             that in the estimation of the primary care practitioner, the patient can reasonably
             be expected to undergo the procedure without significant medical risk to health.

        Exclusion Criteria:

          -  Patients who are not capable of an adequate ophthalmologic examination or evaluation
             to document the pathology.

          -  Patients who are not capable or not willing to undergo follow up eye exams with the
             principle investigator or their ophthalmologist or optometrist as outlined in the
             protocol.

          -  Patients who are not capable of providing informed consent.

          -  Patients who may be at significant risk to general health or to the eyes and visual
             function should they undergo the procedure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Associates of South Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>MD Stem Cells</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Levy, MD</last_name>
    <phone>203-423-9494</phone>
    <email>info@mdstemcells.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Associates of South Florida</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Levy, MD</last_name>
      <phone>203-423-9494</phone>
      <email>info@mdstemcells.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Levy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Al Zahra Private Hospital</name>
      <address>
        <city>Dubai</city>
        <state>UAE</state>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Levy, MD</last_name>
      <phone>(001) 203-423-9494</phone>
      <email>info@mdstemcells.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cells</keyword>
  <keyword>Bone Marrow Derived Stem Cells</keyword>
  <keyword>BMSC</keyword>
  <keyword>BMC (Bone Marrow Cell)</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>MSC</keyword>
  <keyword>Eye Disease</keyword>
  <keyword>Eye Stem Cells</keyword>
  <keyword>Ophthalmology</keyword>
  <keyword>Ophthalmic Disease</keyword>
  <keyword>Retina</keyword>
  <keyword>Retinal Disease</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>Myopic Macular Degeneration</keyword>
  <keyword>Geographic Atrophy</keyword>
  <keyword>Dry Macular Degeneration</keyword>
  <keyword>Wet Macular Degeneration</keyword>
  <keyword>Retinal Atrophy</keyword>
  <keyword>Retinal Dystrophy</keyword>
  <keyword>Hereditary Retinal Dystrophy</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Stargardt Disease</keyword>
  <keyword>Cone Dystrophy</keyword>
  <keyword>Cone Rod Dystrophy</keyword>
  <keyword>Maculopathy</keyword>
  <keyword>Optic Nerve Disease</keyword>
  <keyword>Optic Nerve Atrophy</keyword>
  <keyword>Optic Atrophy</keyword>
  <keyword>Ischemic Optic Neuropathy</keyword>
  <keyword>Optic Nerve Damage</keyword>
  <keyword>Optic Nerve Compression</keyword>
  <keyword>Compressive Optic Neuropathy</keyword>
  <keyword>Devics Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
